Delivery Order SPE2DB20D3101-SPE2DB25FRRA6
- Not listed
- The Defense Logistics Agency awarded a $7,463.51 delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of UBRELVY 100 MG tablets (unit dose, 10-count packages). This firm fixed price delivery order, which is not set-aside designated, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $6,244.42 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packages (16 count) on September 8, 2025, with completion expected by September 9, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of the company's pharmaceutical supply support to federal military and healthcare systems. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $2,126.74 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16 unit dose tablets) on July 18, 2025, with an ultimate completion date of July 21, 2025. This firm fixed price contract, which is not set-aside, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated as SPE2DX, valued at $999,999,999.00 and running through December 2026....
- The Defense Logistics Agency awarded a $3,188.98 firm fixed-price delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 MG tablets (16 unit dose packages) on September 8, 2025, with a completion date of September 9, 2025. This non-set-aside award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle running through December 2026. The place of...
- The Defense Logistics Agency awarded a $5,227.66 delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (unit dose 10s) on July 23, 2025, with completion targeted for July 24, 2025. This competitively awarded, firm fixed-price contract reflects a routine pharmaceutical procurement through the agency's medical supply chain. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,217.32 to AmerisourceBergen Drug Corp for UBRELVY 50 mg tablets (10 unit dose packages) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed price delivery order represents a non-set-aside competitive award and reflects the pharmaceutical distribution services AmerisourceBergen provides to federal medical procurement. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of UBRELVY 100 mg tablets (Unit Dose, 10 count packages) with a ceiling value of $3,362.34. This is a firm fixed-price delivery order with an ultimate completion date of August 25, 2025, and represents a non-set-aside, competitively awarded contract. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packs of 10, with a ceiling value of $8,505.23. This is a firm fixed-price delivery order with an ultimate completion date of September 18, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a $4,831.85 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packaging (10 tablets per dose). This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract. The order is scheduled for completion by July 29, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $1,146.60 delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10 unit dose tablets) on June 17, 2025, with completion scheduled for June 18, 2025. This firm fixed-price, competitively awarded contract utilizes no set-aside designation and identifies Conshohocken, Pennsylvania as the place of performance, which aligns with AmerisourceBergen's corporate headquarters location. The delivery order represents a child contract under...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRRA6Delivery Order
The Defense Logistics Agency awarded a $2,201.13 firm fixed-price delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16 unit dose packs) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside contract is being performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999,999,999.00 prime vehicle running through December 2026 that provides comprehensive global pharmaceutical support to military healthcare systems worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement through its prime IDC with the Defense Logistics Agency. The company's contract portfolio demonstrates extensive capability in supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military and veteran healthcare systems. This delivery order for UBRELVY, a migraine treatment medication, exemplifies the company's ongoing role in fulfilling pharmaceutical needs for the Defense Health Agency and other federal healthcare customers through competitively awarded arrangements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 7/25/25 |